Guangzhou Innogen Pharmaceutical Group Co., Ltd

HK$3.62As of Sun 8 Nov 2026, 12:00 UTC
HKEX:2591Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (41.16%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM (88.16%)
Mkt cap HK$1.654B
ROIC (23.26%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.97
9.68%
(69.92%)
Hold 8|2|1|11|5
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.07
0.07
0.07
0.07
5.06%
16.23%
11.03%
(0.17%)
Revenue¥M
86.18
87.37
85.93
84.99
7.81%
4.31%
0.97%
1.95%
Peers (US$210.9M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
2.444
6.610
5.354
EBIT/Intx
1.496
0.252
0.272
Own earn%
(38.26)
(40.38)
(43.41)
Sh yield%
31.58
20.41
20.87
Owners
Insiders/Inst%
0.11
87.10
Short interest%
1.88
SBC / revenue%
5.49
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
12–19
$1 testx
—
Incr. ROIC%
2